4D Molecular Therapeutics Inc. presented an update on its pipeline, with a focus on advancing its lead product, 4D-150, a gene therapy candidate for wet age-related macular degeneration $(AMD)$. The presentation highlighted significant enrollment progress in the 4FRONT-1 and 4FRONT-2 global clinical trials for retinal vascular diseases, with both studies exceeding initial expectations in patient recruitment. 4D-150 aims to offer a durable, in-office treatment alternative to lifelong injections for large market retinal diseases. The company also outlined ongoing development for additional retinal and pulmonary indications, including geographic atrophy and lung diseases. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.